Q2-osavuosiraportti
Vain PDF
76 päivää sitten
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
3 871
Myynti
Määrä
1 609
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
12,38VWAP
Alin
11,74VaihtoMäärä
0,2 15 032
VWAP
Ylin
12,38Alin
11,74VaihtoMäärä
0,2 15 032
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 13.11. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 21.8. | |
| 2025 Q1-osavuosiraportti | 15.5. | |
| 2024 Yhtiökokous | 28.3. | |
| 2024 Q4-osavuosiraportti | 28.2. | |
| 2024 Q3-osavuosiraportti | 13.11.2024 |
Datan lähde: Millistream, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·3 päivää sittenDoes one have any agreements in place that make sales start immediately after production begins? or does one have to start marketing the product etc. in the USA after one has received approval?
·3 päivää sittenCT-001 will be marketed by Cessatech's partner in the USA, Ventis, under a so-called "Expanded Access Uses" scheme, which is not a real marketing authorization but an approval that allows the product to be sold preliminarily. It requires FDA approval of an IND, including a clinical protocol, which specifies the conditions for how the product can be used, what must be reported to the FDA, etc. In reality, the launch in the USA is to be regarded as a kind of large clinical study. An EAU IND application must, in addition to a clinical protocol and other administrative information, contain information about the manufacturer of the product in the USA as well as information about the manufacturing process. The latter has required a successful technical transfer to STAQ. So, even if it's not directly stated in the press release, it's my guess that one can only now submit an EAU IND, which takes up to 30 days to get approved. At the same time, Ventis must have the treatment guideline for the product approved by various ethical committees, regionally or at individual hospitals (since the product, as mentioned, becomes available under a clinical study). Perhaps one must also agree on price and reimbursement for the product with insurance companies to practically be able to sell it or sell it more successfully to patients who otherwise cannot afford to pay for it. Therefore, it will be a gradual rollout of the product as the individual ethical approvals fall into place (+ P&R). Therefore, Cessatech is probably a bit vague about the launch, as Ventis itself is not in control of the final administrative steps but will have to wait for approvals from ethical committees, etc. The good thing is, 1) that Ventis now has the product ready 2) that Ventis can submit their EAU IND (or get it finalized, if it was already underway but lacked the submission of the last data regarding the manufacturing of the product) - and - 3) can start getting the ethical approvals in place at hospitals (including treatment guidelines) to sell the product. And where Ventis has not appeared super competent regarding 1), they are probably more at home regarding 2) and 3). Until yesterday, there were two categories of obstacles to the product's launch - technical and administrative. While the technical ones are now resolved, the administrative ones remain. But we are getting closer.
·31.10.I'll never understand why one would sell on a day like this, especially with the small increase. They have been working with staq Pharma since January at minimum, they are very far along in the process, but they cannot announce everything yet. But as for me, the uncertainty is gone and I'm mega optimistic! 🍺🍺🍺
·31.10.Could people please be kind enough to adjust the selling price instead of just hitting sell. Please stop setting the sale price 30 øre below the cheapest share.- ·31.10.Jesus in diamond hands. There weren't many we got this time. But yes, we'll probably see each other again when they are to be sold at price 35 🥳
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Q2-osavuosiraportti
Vain PDF
76 päivää sitten
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·3 päivää sittenDoes one have any agreements in place that make sales start immediately after production begins? or does one have to start marketing the product etc. in the USA after one has received approval?·3 päivää sittenCT-001 will be marketed by Cessatech's partner in the USA, Ventis, under a so-called "Expanded Access Uses" scheme, which is not a real marketing authorization but an approval that allows the product to be sold preliminarily. It requires FDA approval of an IND, including a clinical protocol, which specifies the conditions for how the product can be used, what must be reported to the FDA, etc. In reality, the launch in the USA is to be regarded as a kind of large clinical study. An EAU IND application must, in addition to a clinical protocol and other administrative information, contain information about the manufacturer of the product in the USA as well as information about the manufacturing process. The latter has required a successful technical transfer to STAQ. So, even if it's not directly stated in the press release, it's my guess that one can only now submit an EAU IND, which takes up to 30 days to get approved. At the same time, Ventis must have the treatment guideline for the product approved by various ethical committees, regionally or at individual hospitals (since the product, as mentioned, becomes available under a clinical study). Perhaps one must also agree on price and reimbursement for the product with insurance companies to practically be able to sell it or sell it more successfully to patients who otherwise cannot afford to pay for it. Therefore, it will be a gradual rollout of the product as the individual ethical approvals fall into place (+ P&R). Therefore, Cessatech is probably a bit vague about the launch, as Ventis itself is not in control of the final administrative steps but will have to wait for approvals from ethical committees, etc. The good thing is, 1) that Ventis now has the product ready 2) that Ventis can submit their EAU IND (or get it finalized, if it was already underway but lacked the submission of the last data regarding the manufacturing of the product) - and - 3) can start getting the ethical approvals in place at hospitals (including treatment guidelines) to sell the product. And where Ventis has not appeared super competent regarding 1), they are probably more at home regarding 2) and 3). Until yesterday, there were two categories of obstacles to the product's launch - technical and administrative. While the technical ones are now resolved, the administrative ones remain. But we are getting closer.
- ·31.10.I'll never understand why one would sell on a day like this, especially with the small increase. They have been working with staq Pharma since January at minimum, they are very far along in the process, but they cannot announce everything yet. But as for me, the uncertainty is gone and I'm mega optimistic! 🍺🍺🍺
- ·31.10.Could people please be kind enough to adjust the selling price instead of just hitting sell. Please stop setting the sale price 30 øre below the cheapest share.
- ·31.10.Jesus in diamond hands. There weren't many we got this time. But yes, we'll probably see each other again when they are to be sold at price 35 🥳
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
3 871
Myynti
Määrä
1 609
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
12,38VWAP
Alin
11,74VaihtoMäärä
0,2 15 032
VWAP
Ylin
12,38Alin
11,74VaihtoMäärä
0,2 15 032
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 13.11. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 21.8. | |
| 2025 Q1-osavuosiraportti | 15.5. | |
| 2024 Yhtiökokous | 28.3. | |
| 2024 Q4-osavuosiraportti | 28.2. | |
| 2024 Q3-osavuosiraportti | 13.11.2024 |
Datan lähde: Millistream, Quartr
Q2-osavuosiraportti
Vain PDF
76 päivää sitten
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 13.11. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 21.8. | |
| 2025 Q1-osavuosiraportti | 15.5. | |
| 2024 Yhtiökokous | 28.3. | |
| 2024 Q4-osavuosiraportti | 28.2. | |
| 2024 Q3-osavuosiraportti | 13.11.2024 |
Datan lähde: Millistream, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·3 päivää sittenDoes one have any agreements in place that make sales start immediately after production begins? or does one have to start marketing the product etc. in the USA after one has received approval?·3 päivää sittenCT-001 will be marketed by Cessatech's partner in the USA, Ventis, under a so-called "Expanded Access Uses" scheme, which is not a real marketing authorization but an approval that allows the product to be sold preliminarily. It requires FDA approval of an IND, including a clinical protocol, which specifies the conditions for how the product can be used, what must be reported to the FDA, etc. In reality, the launch in the USA is to be regarded as a kind of large clinical study. An EAU IND application must, in addition to a clinical protocol and other administrative information, contain information about the manufacturer of the product in the USA as well as information about the manufacturing process. The latter has required a successful technical transfer to STAQ. So, even if it's not directly stated in the press release, it's my guess that one can only now submit an EAU IND, which takes up to 30 days to get approved. At the same time, Ventis must have the treatment guideline for the product approved by various ethical committees, regionally or at individual hospitals (since the product, as mentioned, becomes available under a clinical study). Perhaps one must also agree on price and reimbursement for the product with insurance companies to practically be able to sell it or sell it more successfully to patients who otherwise cannot afford to pay for it. Therefore, it will be a gradual rollout of the product as the individual ethical approvals fall into place (+ P&R). Therefore, Cessatech is probably a bit vague about the launch, as Ventis itself is not in control of the final administrative steps but will have to wait for approvals from ethical committees, etc. The good thing is, 1) that Ventis now has the product ready 2) that Ventis can submit their EAU IND (or get it finalized, if it was already underway but lacked the submission of the last data regarding the manufacturing of the product) - and - 3) can start getting the ethical approvals in place at hospitals (including treatment guidelines) to sell the product. And where Ventis has not appeared super competent regarding 1), they are probably more at home regarding 2) and 3). Until yesterday, there were two categories of obstacles to the product's launch - technical and administrative. While the technical ones are now resolved, the administrative ones remain. But we are getting closer.
- ·31.10.I'll never understand why one would sell on a day like this, especially with the small increase. They have been working with staq Pharma since January at minimum, they are very far along in the process, but they cannot announce everything yet. But as for me, the uncertainty is gone and I'm mega optimistic! 🍺🍺🍺
- ·31.10.Could people please be kind enough to adjust the selling price instead of just hitting sell. Please stop setting the sale price 30 øre below the cheapest share.
- ·31.10.Jesus in diamond hands. There weren't many we got this time. But yes, we'll probably see each other again when they are to be sold at price 35 🥳
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
3 871
Myynti
Määrä
1 609
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
12,38VWAP
Alin
11,74VaihtoMäärä
0,2 15 032
VWAP
Ylin
12,38Alin
11,74VaihtoMäärä
0,2 15 032
Välittäjätilasto
Dataa ei löytynyt